eprintid: 22474
rev_number: 11
eprint_status: archive
userid: 1589
dir: disk0/00/02/24/74
datestamp: 2017-01-16 09:34:08
lastmod: 2024-03-26 00:23:46
status_changed: 2017-01-16 09:34:08
type: article
metadata_visibility: show
creators_name: Hatiboglu, Gencay
creators_name: Popeneciu, Ionel Valentin
creators_name: Deppert, Matthias
creators_name: Nyarangi-Dix, Joan
creators_name: Hadaschik, Boris
creators_name: Hohenfellner, Markus
creators_name: Teber, Dogu
creators_name: Pahernik, Sascha
title: Quality of life and functional outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer
subjects: 610
divisions: 910200
abstract: Background: To evaluate quality of life, functional and oncological outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer.   Methods: One hundred thirty-one patients, treated with TURP and HIFU in a single institution were followed up for oncological and functional outcome. Oncological outcome was quantified by biochemical recurrence free survival using the Stuttgart and Phoenix criteria. Quality of life was assessed by usage of standardized QLQ-C30 and QLQ-PR25 questionnaires. In addition, functional questionnaires such as IPSS and IIEF-5 were used. Complications were assessed by the Clavien-Dindo classification.   Results: One hundred thirty-one patients with a mean age of 72.8 years (SD: 6.0) underwent HIFU for prostate cancer (29.0% low risk, 58.8% intermediate risk, 12.2% high risk). PSA nadir was 0.6 ng/ml (SD: 1.2) after a mean of 4.6 months (SD: 5.7). Biochemical recurrence free survival defined by Stuttgart criteria was 73.7%, 84.4% and 62.5% for low-, intermediate- and high-risk patients after 22.2 months. Complications were grouped according to Clavien-Dindo and occurred in 10.7% (grade II) and 11.5% (grade IIIa) of cases. 35.1% of patients needed further treatment for bladder neck stricture. Regarding incontinence, 14.3%, 2.9% and 0% of patients had de novo urinary incontinence grade I°, II° and III° and 3.8% urge incontinence due to HIFU treatment. Patients were asked for the ability to have intercourse: 15.8%, 58.6% and 66.7% of patients after non-, onesided and bothsided nervesparing procedure were able to obtain sufficient erection for intercourse, respectively. Regarding quality of life, mean global health score according to QLQ-C30 was 69.4%.   Conclusion: HIFU treatment for localized prostate cancer shows acceptable oncological safety. Quality of life after HIFU is better than in the general population and ranges within those of standard treatment options compared to literature. HIFU seems a safe valuable treatment alternative for patients not suitable for standard treatment.
date: 2017
publisher: BioMed Central
id_scheme: DOI
ppn_swb: 1655907239
own_urn: urn:nbn:de:bsz:16-heidok-224746
language: eng
bibsort: HATIBOGLUGQUALITYOFL2017
full_text_status: public
publication: BMC Urology
volume: 17
number: 5
place_of_pub: London
pagerange: 1-7
issn: 1471-2490
citation:   Hatiboglu, Gencay ; Popeneciu, Ionel Valentin ; Deppert, Matthias ; Nyarangi-Dix, Joan ; Hadaschik, Boris ; Hohenfellner, Markus ; Teber, Dogu ; Pahernik, Sascha  (2017) Quality of life and functional outcome after infravesical desobstruction and HIFU treatment for localized prostate cancer.  BMC Urology, 17 (5).  pp. 1-7.  ISSN 1471-2490     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/22474/1/12894_2017_Article_198.pdf